Navigation Links
Japanese Cancer Association and Debiopharm Honour Professors Minoru Toyota and Keiichi Nakayama With the 2007 JCA-Mauvernay Award
Date:10/8/2007

LAUSANNE, Switzerland, October 8 /PRNewswire/ -- Debiopharm Group (Debiopharm), a global independent biopharmaceutical development specialist in oncology and serious medical conditions, presented Professors Minoru Toyota and Keiichi Nakayama with the 2007 JCA-Mauvernay Award for their outstanding oncology research work. The Awards were presented during the General Assembly of the 66th Annual Conference of the JCA in Yokohama, Japan, by Professor Setsuo Hirohashi, President of the Japanese Cancer Association (JCA) and Dr Rolland-Yves Mauvernay, Founder and President of Debiopharm Group.

The work of Professor Toyota from the First Department of Internal Medicine, Sapporo Medical University, focuses on "DNA methylation as a new target for therapy in cancer". His applied research may lead to novel strategies for developing molecular markers and cancer therapies. DNA methylation of genes could be a useful molecular marker to predict response to chemotherapeutic drugs. The basic research work conducted by Professor Nakayama from the Department of Molecular and Cellular Biology, Medical Institute of Bioregulation, Kyushu University, focuses on "Ubiquitin ligases involved in cell-cycle control and cancer". His work shows that deregulation of the proteolytic system might result in uncontrolled proliferation, genomic instability and cancer. A better understanding of the ubiquitylation machinery will provide new insights into the regulatory biology of cell-cycle transitions and the development of anti-cancer drugs.

"Our goal with this Award is to recognise and reward excellent research conducted by Japanese scientists and to give them the opportunity to show their work to fellow researchers," said Kamel Besseghir, CEO of Debiopharm S.A. "This may increase the chances of their discoveries leading to the development of new medicines."

In its third year, the JCA-Mauvernay Award is organised jointly by the JCA and Debiopharm to honour innovative fundamenta
'/>"/>

SOURCE The Debiopharm Group
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Japanese delegates highlight Wisconsin at BIO Chicago
2. Japanese telecom opens liason office at UW-Platteville
3. Promega, Japanese lab announce partnership
4. Japanese institute installs Imago system
5. Sonic Foundry makes Japanese version of lead product
6. OpGen forges agreement with Japanese importer
7. Japanese biotech is booming and linked with Midwest
8. Japanese institute will develop for UWs Croquet platform
9. 40 Midwest biotech organizations to explore Japanese partnerships
10. Japanese Continue Relentless Biotech Stake in Midwest
11. Tissue Specificity for Mutation Parallels Tissue Specificity for Cancer

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/30/2009)... Minn., Nov. 30 Acuo Technologies,...gement software, data migration tools and services...s and Clinics for a new Vendor Neutral Archive (VN...ss the Allina network of hospitals, clinics and af... the Acuo Technologies DICOM Services Grid(TM) Sof...
(Date:11/30/2009)... 30 Dr. Jessica Torrente, Assistan...ersity Medical Center in Washington, D.C., demonst...amma Imaging (BSGI) in clinical practice as an adj...cancer today at the annual meeting of the Radiolog...urpose of the exhibit was to demonstrate how BSGI ...
(Date:11/30/2009)...E, Nov. 30 Cell Therapeu...today that its new class of platinum-based anti-tu... a stronger anti-tumor potency and activity compar... as well as the ability to overcome cisplatin-resi...sented in a paper titled "Novel Bis-platinum Compl...
(Date:11/29/2009)...able in German . , The concept of confineme...The most famous example is that of quarks which bi.... Bella Lake from Helmholtz-Zentrum Berlin togethe...for the first time an experimental realization and...ondensed matter system. , The concept of confine...
Breaking Biology Technology:Acuo Technologies Announces Contract for Vendor Neutral Archive With Allina Hospitals and Clinics 2Acuo Technologies Announces Contract for Vendor Neutral Archive With Allina Hospitals and Clinics 3Breast-Specific Gamma Imaging In Clinical Practice as an Adjunct Imaging Modality for Diagnosis of Breast Cancer 2New Class of Platinum-Based Anti-Tumor Drugs, Bisplatinates, Demonstrates Potent Anti-Tumor Activity and Ability to Overcome Resistance to Currently Available Platinum-Based Agents 2New Class of Platinum-Based Anti-Tumor Drugs, Bisplatinates, Demonstrates Potent Anti-Tumor Activity and Ability to Overcome Resistance to Currently Available Platinum-Based Agents 3Spinons -- confined like quarks 2
..., SEATTLE, May 8 Dendreon Corporation (Nasdaq: ...ten public offering of 10,700,000 shares of its co...sole manager for the offering. Dendreon has grant...e an additional 1,279,166 shares of common stock t...ntends to use the net proceeds of the offering to ...
..., Conference Call Scheduled Today at 4:30pm ET ,...Expected in 1H 2009 , , Company to Provide Up...ll Today , , Corporate Highlights: , , - ... of Qutenza(TM) (formerly NGX-4010) for treatment ...lts, either alone or in combination with other med...
..., -- Management to host call and webcast today at ... recent business highlights -- , , SAN DIEGO, M...EX ), a biopharmaceutical company focused on the t...ancial results for the three months ended March 31..., As of March 31, 2009, Orexigen held $19.8 millio...
Other Biology Technology:Dendreon Announces Common Stock Offering 2NeurogesX Reports First Quarter 2009 Results 2NeurogesX Reports First Quarter 2009 Results 3NeurogesX Reports First Quarter 2009 Results 4NeurogesX Reports First Quarter 2009 Results 5NeurogesX Reports First Quarter 2009 Results 6NeurogesX Reports First Quarter 2009 Results 7NeurogesX Reports First Quarter 2009 Results 8NeurogesX Reports First Quarter 2009 Results 9NeurogesX Reports First Quarter 2009 Results 10NeurogesX Reports First Quarter 2009 Results 11Orexigen(R) Therapeutics Announces First Quarter 2009 Financial Results 2Orexigen(R) Therapeutics Announces First Quarter 2009 Financial Results 3Orexigen(R) Therapeutics Announces First Quarter 2009 Financial Results 4Orexigen(R) Therapeutics Announces First Quarter 2009 Financial Results 5Orexigen(R) Therapeutics Announces First Quarter 2009 Financial Results 6Orexigen(R) Therapeutics Announces First Quarter 2009 Financial Results 7Orexigen(R) Therapeutics Announces First Quarter 2009 Financial Results 8Orexigen(R) Therapeutics Announces First Quarter 2009 Financial Results 9
(Date:11/30/2009)...us,s exquisite specialisation for its human host ...he humble lab mouse, can deliver only limited info...Med Central,s open access Journal of Biology hav...ating a mouse that has key features of HIV infecti...siotis, from the Division of Immunoregulation at M...
(Date:11/30/2009)...0 Neurotechnology ( http://www.neu...iometric identification technologies, has released...ne: VeriLook 4.0 Software Development Kit (SDK) ...or large-scale multi-biometric and automated finge...abilities in VeriLook 4.0 provide enhanced facial ...
(Date:11/26/2009)...er have been caught in the hunters, sights for gen...decorative. They are lethal weapons that stags cra...niversity of York, UK, has been intrigued by the m...ry and has become fascinated by the mechanical pro...ation with Tomas Landete-Castillejos at the Univer...
Breaking Biology News(10 mins):A reductionist approach to HIV research 2New VeriLook 4.0 for Biometric Facial Recognition and MegaMatcher 3.1 for Multi-biometric Applications Are Now Available 2New VeriLook 4.0 for Biometric Facial Recognition and MegaMatcher 3.1 for Multi-biometric Applications Are Now Available 3Tough yet stiff deer antler is materials scientist's dream 2Rodent size linked to human population and climate change 9434 1Rodent size linked to human population and climate change 9434 2Free Compirion Webinar Promotes Nurse Rounding to Improve Patient Safety 53306 1Free Compirion Webinar Promotes Nurse Rounding to Improve Patient Safety 53306 2Free Compirion Webinar Promotes Nurse Rounding to Improve Patient Safety 53306 3British Woman Celebrates a Year of Living Cancer Free 4803 1British Woman Celebrates a Year of Living Cancer Free 4803 2British Woman Celebrates a Year of Living Cancer Free 4803 3British Woman Celebrates a Year of Living Cancer Free 4803 4
...ous in the early 1980s when they stumbled on small...not only were they not supposed to be there, but t...taching to and detaching from proteins, effectivel...dom was that the job of turning proteins on and of... phosphates, in a common and easy-to-detect chemi...
...t Wake Forest University School of Medicine may be...ntraceptive use dramatically lowers the risk of ov... studying the effect of post-menopausal dietary so... monkeys, Latanya M. Scott, Ph.D., discovered that...in life had a reduced amount of estrogen excreted ...
...oratories engineer, and Bruce Osborn, chief operat... honored with a Popular Mechanics magazine Breakth... the Hearst Tower in New York City. , Sponsored b...lebrate innovations poised to change the world and...ES award is among 21 given by the magazine at the ...
Other Biology News:Johns Hopkins researchers detect sweet cacophony while listening to cellular cross-talk 2Birth control has long-term effect on hormone exposure 2Sandia, SES win Popular Mechanics Breakthrough Innovator Award 2
Epi-Grids Colony Grid Templates-48 Squares from EPICENTRE Biotechnologies
Toxoplasma IgA ELISA Kit, Single from Bio-Quant Inc.
EBV-VCA IgM ELISA Kit, Single from Bio-Quant Inc.
Chlamydia trachomatis IgG ELISA Kit, Single from Bio-Quant Inc.
Biology Products: